No Data
CFRX ContraFect
Watchlist- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About ContraFect Company
ContraFect Corp. is a clinical stage biotechnology company, which engages in the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its product pipeline consists of CF-301, Gram-Negative Lysins, and Amurin Peptides. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.
News
Analysts' Top Healthcare Picks: ContraFect (CFRX), Boston Scientific (BSX)
ContraFect Submits Investigational New Drug Application for Bacterial Pneumonia Treatment
ContraFect (CFRX) said Monday it has submitted an investigational new drug application that supports a proposed indication for CF-370 for the treatment of hospital-acquired bacterial pneumonia and ven
ContraFect Reports Submission Of IND Application To FDA For Its Development Candidate CF-370
The IND application supports a proposed indication for its intravenous (IV) antibacterial agent, CF-370, for treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacteri
Comments
Squeeze Finder Signals
$Boqii(BQ.US$ - the next $Alibaba(BABA.US$
$NFT Gaming(NFTG.US$ - first to market
$GRI BIO(GRI.US$ - float so low you can smell it.
Squeeze Finder
$ContraFect(CFRX.US$ and $NFT Gaming(NFTG.US$
$Genetron(GTH.US$ has also gained alot of attention
Luckyyyyyy : 你也买了这个?
RiveraOP Luckyyyyyy: I have only 100 for now
Luckyyyyyy RiveraOP: What do you think about it, I still hold 2000 shares
RiveraOP Luckyyyyyy: Will pump soon
Luckyyyyyy RiveraOP:

View more comments...